Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Allocetra

Cell therapy · developed by Enlivex Therapeutics

Phase 1/2 Most advanced trial

ENLV Developer

1 Registered trials

What is Allocetra?

Allocetra is a cell-based therapy made of non-HLA-matched allogeneic peripheral blood mononuclear cells induced to an apoptotic stable state. It is being studied in knee osteoarthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy
Therapy area: Musculoskeletal
Developer: Enlivex Therapeutics Ltd. (ENLV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06233474	Phase 1/2	Osteoarthritis, Knee	Active not recruiting	ENLV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Osteoarthritis, Knee

More from Enlivex Therapeutics

Allogeneic Ex-vivo-treated Peripheral Blood Mononuclear Cells Phase 2

Sources

ClinicalTrials.gov NCT06233474

Updated Oct 11, 2026. Something wrong or missing? Report it on the ENLV page.

Follow ENLV, the company behind Allocetra

See ENLV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ENLV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z